A turbulent year for both stocks and bonds may hold some silver linings.
Global Perspectives: Silver lining for equities and bonds in a cloudy market
Making sense of drug pricing reform for investors
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
Global Perspectives: Silver lining for equities and bonds in a cloudy market
A turbulent year for both stocks and bonds may hold some silver linings.
Making sense of drug pricing reform for investors
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
Markets on inflation risks: What, me worry?
The market’s optimistic assessment that inflation can easily be tamed is likely misplaced.
Markets on inflation risks: What, me worry?
The market’s optimistic assessment that inflation can easily be tamed is likely misplaced.
Making sense of drug pricing reform for investors
Why we believe the biopharma industry should be able to adapt to drug pricing changes.
FIP Article 1
The infamous backpedal The UK and US monetary policy meetings in May reminded us of how central banks can backpedal if conditions necessitate. Future progress on economies’ tightening paths can be viewed with this in mind, as QT comes centre stage. The US Federal Reserve (Fed) kicked off its QT programme and raised rates by
Cautious Managed: looking back at H1 2022
Stephen Payne and James Briggs, Co-Managers on the Janus Henderson Cautious Managed Fund, look back at the performance of the strategy in the first half of 2022.
Investor Bias in Global Equities
Portfolio Managers, George Maris and Julian McManus describe their approach to investing in global equities.